Women with androgenetic alopecia have significantly fewer treatment options than men — most of the well-studied oral treatments are contraindicated or inappropriate for women. Spironolactone is a notable exception.
Quick Answer
Spironolactone (25-200mg/day) is one of the most commonly prescribed oral treatments for women with androgenetic alopecia. It works by blocking androgen receptors, reducing DHT's effect on hair follicles. It requires a prescription, ongoing medical supervision, and several months before results become visible.
What Is Spironolactone?
Spironolactone is a potassium-sparing diuretic and aldosterone antagonist originally developed to treat fluid retention, high blood pressure, and heart failure. It was approved by the FDA in 1960 for these cardiovascular indications.
Its off-label use in women — for hormonal acne, polycystic ovary syndrome (PCOS), hirsutism (excess facial/body hair), and androgenetic alopecia — emerged from the discovery of its anti-androgenic properties. Spironolactone is not FDA-approved for any hair loss indication, but it is widely prescribed by dermatologists for female pattern hair loss.
Important upfront: Spironolactone is for women only in the context of hair loss. The anti-androgenic side effects that limit its use in men (gynecomastia, sexual dysfunction, feminization) are acceptable trade-offs for women with androgenetic alopecia, where reducing androgen activity is the therapeutic goal.
How Does Spironolactone Work?
Spironolactone's anti-androgenic effects operate through two mechanisms:
Androgen Receptor Blockade
Spironolactone and its active metabolite (canrenone) competitively bind to androgen receptors, including those in hair follicles. By occupying the receptor, spironolactone prevents DHT and testosterone from binding and triggering follicle miniaturization.
This is different from finasteride's mechanism: finasteride reduces DHT production, while spironolactone blocks DHT's ability to act on the receptor. Both approaches reduce androgen-driven follicle damage.
Reduced Androgen Production
At higher doses, spironolactone may also reduce adrenal androgen production and inhibit some androgen biosynthesis enzymes, providing an additional layer of androgen suppression.
What Does the Evidence Say?
The evidence for spironolactone in female pattern hair loss is positive but comes largely from observational studies and retrospective analyses rather than large randomized controlled trials (RCTs). This is a common limitation in women's hair loss research generally.
Key Studies
A 2005 study by Sinclair et al. in the British Journal of Dermatology followed 80 women with female pattern hair loss treated for at least 12 months with an oral antiandrogen — 40 took spironolactone 200mg/day and 40 took cyproterone acetate. Because results didn't differ between the two drugs, they were reported together: 44% showed regrowth, 44% had no clear change, and 12% continued to lose hair. It was an open, before-and-after study with no placebo group — the authors noted a placebo-controlled study is needed — but the 88% stabilization-or-improvement rate in a condition that usually progresses is encouraging.
A 2020 retrospective review from Massachusetts General Hospital (Burns et al., JAAD) looked at 79 women treated with spironolactone at doses of 25-200mg/day (mean about 100mg). The most common side effect was dizziness or lightheadedness (about 16%); hyperkalemia occurred in one patient and resolved on its own.
A 2023 meta-analysis (Aleissa, Cureus) pooled 5 studies (413 women), only one of them randomized:
- ~57% of women improved overall, with higher rates when spironolactone was combined with other treatments (~66%) than when used alone (~43%)
- ~38% had no or only modest improvement
- Response varied widely between studies
Dose-response evidence is inconsistent: a 2015 UCLA review found no correlation between dose and response.
Spironolactone and minoxidil are both used for female pattern hair loss and are frequently combined, but robust head-to-head trial data directly comparing the two remains limited.
Limitations of the Evidence
The evidence base for spironolactone is significantly smaller than for finasteride in men. Most studies lack placebo controls, and dosing protocols vary widely between studies. This doesn't mean the treatment doesn't work — dermatologists have decades of clinical experience suggesting it does — but it means the evidence is less definitive than ideally desired.
Side Effects
Common and Usually Manageable
- Menstrual irregularities — the most common complaint, particularly early in treatment. Periods may become irregular, lighter, or more frequent. This often stabilizes over time. Women on reliable contraception may not notice this.
- Breast tenderness or enlargement — mild, usually resolves with continued use
- Increased urination — from the diuretic effect; usually diminishes with continued use
- Dizziness or lightheadedness — particularly on standing (orthostatic hypotension), especially in the first weeks. Take at night or with food.
- Fatigue — reported by some women, usually transient
Important Monitoring: Potassium
Spironolactone is a potassium-sparing diuretic, meaning it can raise serum potassium levels (hyperkalemia). In healthy young women without kidney disease or other risk factors, clinically significant hyperkalemia at typical hair loss doses (25-200mg) is rare — a study of 974 healthy young women taking spironolactone for acne found hyperkalemia no more often than in women not taking it, and concluded routine potassium monitoring was unnecessary in that group. However:
- Many prescribers still check a baseline potassium level, and testing matters more for older women (in a 2026 study of women 45 and over, mostly mild hyperkalemia occurred in about 10%, and in 22% of those 65 or older), anyone with kidney problems, and anyone taking other drugs that raise potassium
- Avoid high-potassium salt substitutes (e.g., "lite salt") and potassium supplements unless your doctor approves them
- Follow your prescriber's monitoring plan; it should be more frequent with kidney concerns or interacting medications
Contraception Requirement
Spironolactone carries a pregnancy risk — its FDA label warns that, based on its mechanism and animal studies (which showed feminization of male fetuses), it "may affect sex differentiation of the male during embryogenesis," though human data is very limited. Most prescribing physicians require women of reproductive age to use reliable contraception while on spironolactone. This is often combined with the oral contraceptive pill, which may itself have anti-androgenic benefits for hair loss.
What Spironolactone Does Not Cause
Sexual side effects are not among the commonly reported problems for women taking spironolactone for hair loss or acne. They are not impossible, though — decreased libido is listed among the drug's possible adverse reactions — so mention any change to your prescriber.
Who Is It For?
Women who may benefit most
- Women with confirmed androgenetic alopecia (female pattern hair loss) — the population with the strongest evidence
- Women with signs of elevated androgens — elevated DHEA-S, testosterone, concurrent hormonal acne, or hirsutism; spironolactone addresses both hair loss and other androgen-excess symptoms
- Women with PCOS — spironolactone is a common component of PCOS management that can address hair loss alongside other manifestations
- Post-menopausal women — reasonable option, though hormonal evaluation first is warranted
Who should avoid or be cautious
- Women trying to conceive — spironolactone should be stopped before attempting pregnancy
- Women with kidney disease or impaired kidney function — hyperkalemia risk is significantly higher
- Women with low blood pressure — diuretic effects may worsen hypotension
- Women taking potassium supplements, ACE inhibitors, ARBs, NSAIDs, or trimethoprim — drug interactions that increase hyperkalemia risk
Typical Doses
Dosing for hair loss ranges from 25-200mg/day, with many dermatologists starting low (often 25-50mg) and titrating up based on response and tolerability. A common protocol:
- Start: 50mg/day for 1-2 months
- Titrate: Increase to 100mg/day if tolerated
- Consider 150-200mg if partial response at 100mg
Whether higher doses work better is unclear — retrospective data are inconsistent — but higher doses do bring more side effects, particularly menstrual irregularity.
Cost and Access
Generic spironolactone is very affordable — typically $10-25/month at most pharmacies, making it one of the most cost-effective hair loss treatments available.
It requires a prescription. Access options:
- Dermatologist — standard route; may require in-person visit and bloodwork
- Gynecologist or endocrinologist — often prescribe for hormonal indications including hair loss
- Telehealth platforms specializing in women's health increasingly prescribe spironolactone for hair loss with online consultation
Our Verdict
Spironolactone is among the best-supported oral treatments available for women with androgenetic alopecia — a category where options are genuinely limited. The evidence isn't as robust as finasteride's in men, but decades of real-world dermatology practice back it up, and the safety profile is well-characterized.
If you're a woman with female pattern hair loss or signs of androgen excess, a conversation with a dermatologist or your gynecologist about spironolactone is warranted. The low cost and accessible monitoring requirements make it a practical long-term option.
Sources
- Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology. 2005;152(3):466-473. PMID: 15787815.
- Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatologic Clinics. 2010;28(3):611-618. PMID: 20510769.
- Burns LJ, De Souza B, Flynn E, et al. Spironolactone for treatment of female pattern hair loss. Journal of the American Academy of Dermatology. 2020;83(1):276-278. PMID: 32259535.
- Layton AM, Eady EA, Whitehouse H, et al. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. American Journal of Clinical Dermatology. 2017;18(2):169-191. PMID: 28155090.
- Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus. 2023;15(8):e43559. PMID: 37719557.
- Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. Journal of the American Academy of Dermatology. 2015;73(4):705-706. PMID: 26369846.
- Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatology. 2015;151(9):941-944. PMID: 25796182.
- Gregoire S, Dewey E, Sanchez K, et al. Hyperkalemia incidence in females over 45 years old on spironolactone for dermatologic conditions: a retrospective cohort study. Journal of the American Academy of Dermatology. 2026;94(6):1671-1678. PMID: 41655839.
Spironolactone is a generic prescription medication. We do not have an affiliate relationship with any pharmacy for this product.